SEZ6L2
Seizure 6-like protein 2
Also known as: FLJ90517, PSK-1, SE6L2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6UXD5
- Gene
- SEZ6L2
- Ensembl
- ENSG00000174938
- Chromosome
- 16
- Canonical length
- 910 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
This gene encodes a seizure-related protein that is localized on the cell surface. The gene is located in a region of chromosome 16p11.2 that is thought to contain candidate genes for autism spectrum disorders (ASD), though there is no evidence directly implicating this gene in ASD. Increased expression of this gene has been found in lung cancers, and the protein is therefore considered to be a novel prognostic marker for lung cancer. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Aug 2011]
Canonical amino-acid sequenceUniProt
910 residues, UniProt reviewed canonical sequence.
>Q6UXD5|SEZ6L2
1 MGTPRAQHPP PPQLLFLILL SCPWIQGLPL KEEEILPEPG SETPTVASEA LAELLHGALL
61 RRGPEMGYLP GSDRDPTLAT PPAGQTLAVP SLPRATEPGT GPLTTAVTPN GVRGAGPTAP
121 ELLTPPPGTT APPPPSPASP GPPLGPEGGE EETTTTIITT TTVTTTVTSP VLCNNNISEG
181 EGYVESPDLG SPVSRTLGLL DCTYSIHVYP GYGIEIQVQT LNLSQEEELL VLAGGGSPGL
241 APRLLANSSM LGEGQVLRSP TNRLLLHFQS PRVPRGGGFR IHYQAYLLSC GFPPRPAHGD
301 VSVTDLHPGG TATFHCDSGY QLQGEETLIC LNGTRPSWNG ETPSCMASCG GTIHNATLGR
361 IVSPEPGGAV GPNLTCRWVI EAAEGRRLHL HFERVSLDED NDRLMVRSGG SPLSPVIYDS
421 DMDDVPERGL ISDAQSLYVE LLSETPANPL LLSLRFEAFE EDRCFAPFLA HGNVTTTDPE
481 YRPGALATFS CLPGYALEPP GPPNAIECVD PTEPHWNDTE PACKAMCGGE LSEPAGVVLS
541 PDWPQSYSPG QDCVWGVHVQ EEKRILLQVE ILNVREGDML TLFDGDGPSA RVLAQLRGPQ
601 PRRRLLSSGP DLTLQFQAPP GPPNPGLGQG FVLHFKEVPR NDTCPELPPP EWGWRTASHG
661 DLIRGTVLTY QCEPGYELLG SDILTCQWDL SWSAAPPACQ KIMTCADPGE IANGHRTASD
721 AGFPVGSHVQ YRCLPGYSLE GAAMLTCYSR DTGTPKWSDR VPKCALKYEP CLNPGVPENG
781 YQTLYKHHYQ AGESLRFFCY EGFELIGEVT ITCVPGHPSQ WTSQPPLCKV TQTTDPSRQL
841 EGGNLALAIL LPLGLVIVLG SGVYIYYTKL QGKSLFGFSG SHSYSPITVE SDFSNPLYEA
901 GDTREYEVSILocalizationUniProt · AlphaFold · HPA
Whether an antibody against SEZ6L2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 99 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 99 nTPM
- pituitary gland: 88 nTPM
- hypothalamus: 74 nTPM
- cerebral cortex: 73 nTPM
- hippocampal formation: 42 nTPM
- basal ganglia: 41 nTPM
Single-cell type
- pancreatic islet cells: 289 nCPM
- corticotrophs: 224 nCPM
- other brain neurons: 176 nCPM
- retinal bipolar cells: 158 nCPM
- retinal amacrine cells: 142 nCPM
- brain inhibitory neurons: 139 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 245 nTPM
- hypothalamus: 236 nTPM
- pons: 180 nTPM
- white matter: 154 nTPM
- basal ganglia: 135 nTPM
- medulla oblongata: 132 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SEZ6L2.
Disease | AutoantibodyPubMed
Conditions in which antibodies against SEZ6L2 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for SEZ6L2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy.
2014 · J Neurol · RCR 1.3 · 40 citations - Anti-Sez6l2 antibody detected in a patient with immune-mediated cerebellar ataxia inhibits complex formation of GluR1 and Sez6l2.
2018 · J Neurol · RCR 0.8 · 19 citations - Sez6L2 autoimmunity induces cerebellar ataxia in mice.
2025 · J Neuroinflammation · 3 citations - Sez6L2 autoimmunity induces cerebellar ataxia in mice.
2025 · bioRxiv · 1 citations - Anti-Sez6L2 antibody-associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy.
2026 · Neurol Sci
Show 1 more
- Clinical Spectrum of Anti-SEZ6L2 Syndrome: A Case Report With Brain Volumetry and Systematic Literature Review.
2026 · Neurol Neuroimmunol Neuroinflamm
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.42
- gnomAD pLI
- 0.12
- gnomAD missense Z
- 1.75
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SEZ6L2 as an antibody target. Whether an autoantibody or antibody against SEZ6L2 could matter depends on whether native SEZ6L2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SEZ6L2 is annotated at the cell surface, where native SEZ6L2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SEZ6L2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...